BioHealth Innovation clients Alex Lai (Speed BioSystems), Matthew Mulvey (Benevir), David Cetlin (MockV Solutions), and BHI Entrepreneur-in-Resident Ram Aiyar meet with Bahija Jallal.
Dr. Bahija Jallal is Executive Vice President, MedImmune, responsible for biologics research, development and clinical activities. As part of AstraZeneca’s Senior Executive Team, Bahija is tasked with advancing the biologic organisation’s pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardiovascular and gastrointestinal disorders and pain. (Astrazenica Bio)
Biopharmaceutical company Emergent BioSolutions could begin manufacturing an experimental Ebola drug at its Baltimore facility.
Rockville-based Emergent is one of three advanced laboratories asked by the Biomedical Advanced Research and Development Authority (BARDA) to submit a plan for manufacturing ZMapp. The drug has been used among infected health workers in Africa but supplies have run out. BARDA will select one or more of the labs to make more of the drug.
Summary of Position: The Director, Regulatory Affairs is the regulatory representative on the Product Development Teams providing regulatory support and advice. The Director will facilitate regulatory strategy development and implementation, take the lead on regulatory submissions, and author, review, and coordinate quality submissions to regulatory agencies. The Director will prepare for meetings, teleconferences, and other communications with FDA, educate teams regarding regulatory risks and implications for strategy and product development activities, and utilize technical knowledge and effectively apply regulations and guidelines to the product development process.
Vanessa Sorto Accounting and Human Resources Intern
Vanessa Sorto joined BHI on September 2014 as an accounting and human resources intern. She is responsible for supporting the director of finance and human resources in assembling monthly expense reports for BHI senior staff, reconciling bank accounts, preparing monthly financial reports, assisting in audit preparation, and maintaining payroll. She is currently pursuing a bachelor’s degree at The University of Maryland, College Park in Accounting and Information Systems. She is a Hillman Entrepreneur scholarship recipient.
Kurt Herzog Business & Research Analyst
Kurt Herzog joined BHI in 2014 as a Business & Research Analyst. He assists BHI’s client companies with market entry strategies for their products by engaging with clients to understand current products, researching existing and potential markets, and analyzing business strategy. His work includes developing executive summaries, investor slide decks, tailored presentation materials, and creating financial models for presentation to investors.
Kurt also works with Tania Fernandez on the BioHealth Gap Fund, a $50 million fund announced October 2014 in partnership with the EAGB to support early-stage therapeutics, medical device, diagnostics, and health IT companies in central Maryland. Kurt has experience in investment banking, international micro-lending, renewable energy project finance and project development, forest carbon sequestration monitoring, institutional investing in hedge funds, and working for a non-profit startup accelerator. Kurt holds a BA in Economics and Environmental Studies with a Natural Science concentration from Bowdoin College. He also completed substantial coursework in chemistry.
Don’t miss the third annual full-day Innovation 2 Commercialization (I2C) conference featuring three informative plenary sessions to help launch, commercialize and fund YOUR technology to make your business venture profitable!
Hear panels on innovation, commercialization and financing featuring speakers from MedImmune, Brain Sentry, Naval Research Lab and more. Plus, learn about the “Amplimmune Story” and enjoy lunch as you discuss issues affecting your innovation or small business with a subject matter expert from a federal lab, university tech transfer office, venture capital firm, business service organization and others who serve as your table host.
Join the BioBuzz networking group at our next free event. Along with 100’s of the region’s bioscience workers, you too could be making new connections, getting jobs and helping to build a stronger, more connected industry through the BioBuzz community!
The event is always free and we offer free drinks to the first 50 to 100 who arrive depending on how much we’ve been sponsored on a given month. People from all around the the region are coming out each month for this unique and welcoming monthly happy hour. It’s a great place to meet up with coworkers past and present, make new connections or just catch up on the latest industry gossip If you’re new and haven’t yet made it out to an event, then we hope that you’ll join us this month and see what all the Buzz is all about.
One of the two Ebola-infected Dallas nurses was admitted to a National Institutes of Health biocontainment unit in Bethesda on Thursday, just as researchers at the University of Maryland School of Medicine in Baltimore are beginning the first human trials of an Ebola vaccine in Africa.
Dr. Myron Levine, a researcher at the medical school, is a member of the international medical group leading the efforts to end the outbreak. Ebola has infected more than 8,000 people since the first reported case in March, according to the Centers for Disease Control and Prevention.
Applications are now open for DreamIt Health’s second Baltimore cohort.
DreamIt Ventures will accept applications through Dec. 5, according to a DreamIt blog post. The first cohort last year included startups like Protenus, Aegle and Quantified Care.
ASTRAZENECA has announced a four-way collaboration which will strengthen the pharmaceutical giant’s link with Cambridge University.
The firm, together with its biologics research and development arm MedImmune, has agreed the new collaboration as it prepares to move its global headquarters to the city. It builds on an existing strategic partnership between the organisations.
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association for life science and technology, has been awarded a three-year, $225,000 federal grant designed to help job seekers gain skills in the growing fields of cyber technology and cyber security.
The grant is part of a $15 million federal investment in the Cyber-Technology Pathways Across Maryland (C-PAM) Consortium, spearheaded by Montgomery College. The consortium, which is comprised of 14 community colleges and trade associations, aims to prepare women and other underrepresented populations for jobs in the rapidly growing cyber industry.
Sucampo Pharmaceuticals has announced that it signed an amendment to the existing collaboration and license agreement (Collaboration Agreement) covering the United States and Canada for AMITIZA(R) (lubiprostone) with Takeda Pharmaceutical Company Ltd. The amendment includes various modifications to the Collaboration Agreement including the extension of the current term, minimum commercial investment during the current term and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA.
During the extended term, which will begin on January 1, 2021, Takeda will split with Sucampo the gross profits of branded AMITIZA for any dosage strength and form for the existing indications in the U.S. and Canada. In addition, on April 1, 2015 Takeda will no longer reimburse Sucampo for the product details made by Sucampo sales representatives to healthcare professionals as well as other ancillary costs of the sales force.
As the tech industry falls back in love with urban America, Joel Marcus, landlord to the booming biotechnology business, is perfectly positioned to strike it rich.
In Manhattan, overlooking the East River and sandwiched between New York University Langone Medical Center and Bellevue Hospital, two gleaming 16-story towers act as beacons to the booming biotech sector.
Completed in 2010, the 310,000-square-foot Alexandria Center for Life Science is already 100% occupied. It contains a hub for Eli Lilly’s cancer business and a Pfizer PFE -1.69% lab dedicated to exploring leads generated by academic researchers. The second building, some 410,000 square feet of labs and office space, was finished in January and is already 60% full. Roche, the anchor tenant, says moving 250 clinical trial specialists there from Nutley, N.J. has resulted in 25 new collaborations with charities, biotechs and New York hospitals. There’s also an accelerator for startups, an enviro-friendly garden and fancy restaurants to feed all those scientists.
Becton Dickinson (NYSE: BDX) has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols – from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications.
“We are excited with the GenCell Biosystems acquisition as it provides BD entry into the Next Generation Sequencing market, a fast-growing segment with the potential to have a significant impact on healthcare,” said Linda Tharby, Group President, BD. “The acquisition gives BD access to the NGS market with a differentiated platform that will provide a base to further grow our genomics offerings.”
QIAGEN N.V. (NASDAQ: QGEN)(Frankfurt Prime Standard: QIA) announced today that its business area, QIAGEN Bioinformatics, has been named by Genomics England (GeL) an assessment winner for the UK100K project, along with other life science technology providers. The company will be providing project researchers access to Ingenuity® Variant Analysis™, a powerful web-application that allows users to rapidly identify and prioritize disease causing genetic variants using advanced analytics powered by published biological evidence and large numbers of sequenced genomes.
Bicycle’s founding venture capitalist (VC), Atlas Ventures joined forces this month with SV Life Sciences and three corporate VCs – Novartis (NVS) Venture Fund, GlaxoSmithKline’s (GSK) SR One and Astellas Venture Management to invest $32m (€25m) in the Cambridge-based biotech company.
Bicycle Therapeutics was established in 2009 as a spin-off of the Medical Research Council Laboratory of Molecular Biology (Cambridge), based on the work of the scientific founders Sir Gregory Winter and Professor Christian Heinis from Trinity College, Cambridge. Winter, a renowned scientist in the biotech industry, also founded Domantis and Cambridge Antibody Technology. Founded in the 80s, Cambridge Antibody Technology was a pioneer in British biotechnology, and was listed on the UK stock exchange in 1997, raising £43m. In 2006, AstraZeneca bought the company.
A $5 million Innovation Challenge Fund (ICF), to encourage and support academic groups and small companies in collaborative efforts in the development of bioelectronic medicines, has been announced by GSK. This funding programme is in addition to the company’s prior commitment of a $1 million award (December 2013), for the team that first solves the GSK Bioelectronics Challenge.
Bioelectronic medicine is focused on producing miniaturised, implantable devices that could be programmed to read and correct electrical signals passing along the nerves of the body, to treat disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes. The ICF funded work and the Innovation Challenge’s winning entry will be made freely available to the global research community.
Venture capital investments in Maryland are still working their way back up, according to a report released this week by PricewaterhouseCoopers and the National Venture Capital Association.
In the third quarter of 2014, venture capitalists spent $89 million, up 34 percent from the second quarter’s $66.5 million, but far off the third quarter number from last year, which hit $142 million, according to the report.
In the Boston-versus-New York rivalry, the Red Sox and the Yankees were also-rans this baseball season. Now, Massachusetts and New York are in another battle for the No. 2 spot: U.S. venture capital investment.
New York is leading Massachusetts in total venture capital invested so far this year, which if it held up would be the first time the Empire State edged out its East Coast rival and took second place behind industry leader California since at least 1992.
A BIOTECHNOLOGY company founded by Limerick man Kieran Curran has been snapped up for $150m by a US firm.
GenCell Biosystems, a company based in Raheen with offices in the US, was acquired late last week by Becton Dickinson, a company listed on the New York Stock Exchange.
ATCC, the premier global biological materials resource and standards organization, announces the release of ATCC® Minis to support quality control (QC) testing in pharmaceutical and industrial labs, during the PDA 9th Annual Global Conference on Pharmaceutical Microbiology in Bethesda, MD, Booth # 304.
Healthcare, personal care product, and cosmetic manufacturers are required to test the bio-burden and sterility of their products and production environments to ensure consumer safety. Global alignment and harmonization of microbial testing requirements among the United States Pharmacopeia (USP), Japanese Pharmacopeia (JP), and European Pharmacopeia (EP), have resulted in the need for consistent and reliable control organisms at less than five passages from the ATCC reference stock for reproducible results.
A jaw-dropping report released by the World Health Organization on October 14, 2014 reveals that 1 in 20 Ebola infections has an incubation period longer than the 21 days which has been repeatedly claimed by the U.S. Centers for Disease Control.
This may be the single most important — and blatantly honest — research report released by any official body since the beginning of the Ebola outbreak. The WHO’s “Ebola situation assessment” report, found here, explains that only 95% of Ebola infections experience incubation within the widely-reported 21-day period.
I joined J&J Consumer Companies about four years ago to start its Digital Center of Excellence. Our role initially was to build capabilities and develop strategy that served multiple brands in multiple regions, so I did a landscape overview to help develop the approach. What I saw was that we had hundreds of different websites and digital platforms that we were operating upon globally. If you want to get a message across globally on your owned assets, you need to do that in the same way across the world.
The Center for Innovative Technology (CIT) announced this week the release of the Commonwealth Research Commercialization Fund (CRCF) annual report for FY2014, showing growth in new patents, products and innovative companies.
Karen Jackson, Virginia’s Secretary of Technology, said, “CRCF plays an important role in the acceleration of innovation in the Commonwealth by funding essential research and commercialization projects. The investments we make in research commercialization plant the seeds that are growing the New Virginia Economy.”
Bioinformatics giant Illumina (NASDAQ: ILMN) is getting into the accelerator game, along with other players in the life sciences and other fields. On Wednesday it announced the first three startups chosen to start the program this fall at its San Francisco lab space.
San Diego-based Illumina, which makes genomic analysis systems, unveiled the program in February, joining the growing list of academic institutions, venture-backed groups, and life science corporations building start-up space in the Bay Area and beyond. Not least among the benefits of the Illumina accelerator program is access to the company’s high-end gene sequencing systems, which are installed in the lab space Illumina has leased near the Mission Bay campus of the University of California, San Francisco.
The Eastern Shore Entrepreneurship Center (ESEC), Rural Maryland Council (RMC), and Maryland Capital Entreprises (MCE) have joined together to offer the third annual Eastern Shore Business Competition. All three organizations strive to advance and expand the entrepreneurial ecosystem on Maryland’s Eastern Shore, as well as throughout Maryland, and collaborate to execute a business competition that will draw greater attention to the Eastern Shore and attract entrepreneurs to the opportunities and resources available in the region. The application process for the competition has begun and we are looking forward to your submissions!
The purpose of the competition is to promote and encourage the startup of new businesses and in turn the creation of new jobs on Maryland’s Eastern Shore.
Ideas are the juice that powers our economy with innovation happening fast on multiple technology fronts. Rapid developments are in play in areas as diverse as 3D printing, Ultra HD, sensors, health care, automotive electronics, agriculture, transportation, biotech and genetic mapping.
The $211 billion consumer electronics (CE) industry is at the vanguard of innovation. Just last year, the U.S. Patent Office issued a record 277,835 patents. We are at the beginning of a surge of technology advances that we will all benefit from.
On a massive bus in the heart of America, a group of tech entrepreneurs and investors are spreading glad tidings about entrepreneurship and startups in cities that don’t exactly scream innovation. Many people have tried to jumpstart the innovation engine across the country, but few have as much experience and clout to pull it off as Steve Case, co-founder of AOL, and chairman of DC-based investment firm Revolution.
Chairs: we sit in them, work in them, shop in them, eat in them and date in them. Americans sit for most of their waking hours, 13 hours every day on average. Yet chairs are lethal.
This grim conclusion may surprise you, but 18 studies reported during the past 16 years, covering 800,000 people overall, back it up. In 2010, for example, the journal Circulation published an investigation following 8,800 adults for seven years.
The National Institutes of Health (NIH) has launched a pilot program to help life science entrepreneurs commercialize their technology, based on a course developed by the University of California, San Francisco. The course was first taught last fall by the Entrepreneurship Center at UCSF and Steve Blank, architect of the Lean LaunchPad framework. UCSF and Blank adapted the Lean LaunchPad methodology to be applicable for life science and healthcare ventures.
Antibiotic resistance is taking its toll on the pharmaceutical industry: Drugs are getting retired from clinical circulation, because many are starting to get rendered ineffective, according to an article from Washington University of St. Louis. It highlights the work of WUSTL’s Michael Kinch, associated vice chancellor of its Center for Research Innovation in Business:
University of Maryland, Baltimore’s $200 million proton therapy center will begin treating cancer patients in a year.
The center’s first of five treatment rooms will begin treating patients in October 2015. The entire building is expected to be complete in two years. The 110,000-square-foot building is part of the University of Maryland BioPark in Baltimore off Martin Luther King Boulevard.
The Center for the Advancement of Science in Space (CASIS) has announced grant awards for three projects focused on enabling technologies from the International Space Station (ISS). These awards stem from the CASIS Request for Proposals (RFP) “Enabling Technology to Support Science in Space for Life on Earth.” CASIS is the nonprofit organization managing research onboard the ISS U.S. National Laboratory.
The purpose of this RFP was to identify and support technology development projects that would enable increased use of ISS for Earth benefits—for example, improvements in hardware/capabilities or methods to improve bandwidth, throughput, or quality of future research projects.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Summary of Position:
